Fiasp is not a long-acting insulin. It is a rapid-acting mealtime insulin designed to work faster than traditional rapid-acting options. Its effects last only 3 to 5 hours, compared to long-acting insulins that work steadily for 24 hours or more.
How Fiasp Is Classified
Fiasp is a faster-formulated version of insulin aspart, the same active ingredient found in NovoLog. It falls into the rapid-acting category of insulins, sometimes called “ultra-rapid-acting” because of how quickly it starts working after injection. The FDA-approved label instructs users to inject Fiasp at the start of a meal or within 20 minutes after starting a meal, which reflects its purpose: covering the blood sugar spike that comes from eating.
Long-acting insulins, by contrast, are “basal” insulins injected once or twice a day to provide a low, steady level of insulin around the clock. They have no sharp peak and last anywhere from 20 to 42 hours depending on the type. Fiasp does the opposite: it hits hard and fast, then clears the body within a few hours.
How Fiasp Works So Quickly
What makes Fiasp faster than standard insulin aspart is a reformulation, not a new insulin molecule. The manufacturer added two ingredients to the existing insulin aspart formula. The first is niacinamide (a form of vitamin B3), which helps insulin molecules break apart more rapidly after injection and increases local blood flow at the injection site, speeding absorption. The second is L-arginine, which stabilizes the formulation so it stays effective in the vial or pen.
The result is that Fiasp reaches the bloodstream sooner than standard insulin aspart. This earlier onset can help blunt post-meal blood sugar spikes more effectively, particularly in the first hour after eating.
Onset, Peak, and Duration
Rapid-acting insulins like Fiasp share a general duration profile of 3 to 5 hours. Within that window, Fiasp begins working within minutes of injection, peaks relatively quickly, and then tapers off. This is a stark contrast to the long-acting insulin profile:
- Rapid-acting (Fiasp, NovoLog, Humalog): onset within minutes, duration of 3 to 5 hours
- Long-acting (Lantus, Levemir, Tresiba): gradual onset, duration of 20 to 42 hours
If you’re using Fiasp, you almost certainly need a separate long-acting insulin (or an insulin pump delivering a continuous basal rate) to cover your body’s baseline insulin needs between meals and overnight. Fiasp handles the meal; basal insulin handles the rest of the day.
When and Where to Inject Fiasp
Because Fiasp is designed for mealtime use, the timing window is tight. You can inject it right as you sit down to eat or up to 20 minutes into the meal. This flexibility is one of its advantages over older rapid-acting insulins, which typically need to be injected 15 minutes before a meal for best results.
Injection sites include the abdomen, upper arm, or thigh. The abdomen generally provides the fastest absorption for subcutaneous insulin, though rotating sites is important to avoid tissue changes over time. Fiasp can also be used in insulin pumps for continuous delivery.
Why the Confusion Happens
People new to insulin therapy often encounter a confusing landscape of brand names without clear labels telling them which category each product belongs to. The name “Fiasp” doesn’t obviously signal “fast-acting” the way some might expect. If you’re trying to sort out your insulin regimen, the simplest rule is this: mealtime insulins (rapid-acting) are taken with food and wear off in hours, while basal insulins (long-acting) are taken on a fixed schedule regardless of meals and last most or all of the day. Fiasp is firmly in the mealtime camp.